Dr Melanie Saville | VP, Head of Late Development, Clinical and Medical Affairs
Janssen Vaccines & Prevention B.V.

Dr Melanie Saville, VP, Head of Late Development, Clinical and Medical Affairs, Janssen Vaccines & Prevention B.V.

Melanie Saville is Head of Late Development, Clinical and Medical Affairs at Janssen Vaccines. She is a physician specialized in virology with more than 15 years’ experience in the vaccine industry.
Joining Wyeth in 2000 in the UK, Melanie led the phase III clinical development of a live attenuated intranasal influenza vaccine. In addition she contributed to a number of vaccine projects in early development involving adjuvants, immune modulators, viral vectors and conjugate technology.
In 2004 she joined Sanofi Pasteur in Lyon, France where she initially led the clinical influenza franchise having oversight of the clinical development of a number of differentiated seasonal influenza vaccine and pandemic vaccines. She then led the clinical development of a candidate dengue vaccine moving into phase III. Subsequently she became the Head of Clinical Development for a portfolio of vaccine projects managed out of the EU site. In 2013 she took on a broad role of Chief Medical and Clinical officer Dengue having responsibility for licensure of the candidate Dengue vaccine until the end of 2015. Over the years, she has contributed to the licensure of a number of vaccines for seasonal and pandemic influenza, pediatric combinations, Rabies and Japanese Encephalitis and Dengue in Europe, US and the international area.
Prior to joining industry, Melanie worked as a clinical virologist and conducted research at the Health protection Agency in London in the field of RSV and HSV.
Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a Masters in Medical Virology from Imperial College, London.


Day Two 11th October, Human @ 14:45

The challenges of clinical development for emerging infectious diseases – The Example of Ebola

Day Two 11th October, Human @ 17:00

Interactive panel: accelerated development of vaccine products to human clinical trials – successes and challenges

More panellists to be announced shortly

back to speakers